ArticleMarine drugs2014
Construction and characterization of an Escherichia coli mutant producing Kdo₂-lipid A.
Article in Marine drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 58 citations in OpenAlex.
- Polyphosphate kinase regulates LPS structure and polymyxin resistance during starvation in E. coli.PLoS biology · 2024Article
- Impact of cell wall polysaccharide modifications on the performance of Pichia pastoris: novel mutants with enhanced fitness and functionality for bioproduction applications.Microbial cell factories · 2024Article
- Membrane-Disruptive Effects of Fatty Acid and Monoglyceride Mitigants onMolecules (Basel, Switzerland) · 2024Article
- Escherichia coli displays a conserved membrane proteomic response to a range of alcohols.Biotechnology for biofuels and bioproducts · 2023Article
- Lipopolysaccharide structure modulates cationic biocide susceptibility and crystalline biofilm formation inFrontiers in microbiology · 2023Article
- A Lipopolysaccharide Synthesis GeneMicroorganisms · 2022Article
- Hyperproduction of PHA copolymers containing high fractions of 4-hydroxybutyrate (4HB) by outer membrane-defected Halomonas bluephagenesis grown in bioreactors.Microbial biotechnology · 2022Article
- Engineering the Outer Membrane Could Facilitate Better Bacterial Performance and Effectively Enhance Poly-3-Hydroxybutyrate Accumulation.Applied and environmental microbiology · 2021Article
- Core Oligosaccharide Portion of Lipopolysaccharide Plays Important Roles in Multiple Antibiotic Resistance in Escherichia coli.Antimicrobial agents and chemotherapy · 2021Article
- Insights into the structure of Escherichia coli outer membrane as the target for engineering microbial cell factories.Microbial cell factories · 2021Review
- The Characterization of Two-Component System PmrA/PmrB inFrontiers in microbiology · 2020Article
- A Metagenome-Wide Association Study and Arrayed Mutant Library ConfirmG3 (Bethesda, Md.) · 2018Article
- AlmG, responsible for polymyxin resistance in pandemicThe Journal of biological chemistry · 2017Article
- Mutation of the Enterohemorrhagic Escherichia coli Core LPS Biosynthesis Enzyme RfaD Confers Hypersusceptibility to Host Intestinal Innate Immunity In vivo.Frontiers in cellular and infection microbiology · 2016Article
- Comparative analysis of lipopolysaccharides of pathogenic and intermediately pathogenic Leptospira species.BMC microbiology · 2015Article
- Influence of Core Oligosaccharide of Lipopolysaccharide to Outer Membrane Behavior of Escherichia coli.Marine drugs · 2015Article
- Immuno-Stimulatory Activity of Escherichia coli Mutants Producing Kdo2-Monophosphoryl-Lipid A or Kdo2-Pentaacyl-Monophosphoryl-Lipid A.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3-deoxy-D-manno-oct-2-ulosonic acid (Kdo)₂-lipid A is the conserved structure domain of lipopolysaccharide found in most Gram-negative bacteria, and it is believed to stimulate the innate immune system through the TLR4/MD2 complex. Therefore, Kdo₂-lipid A is an important stimulator for studying the mechanism of the innate immune system and for developing bacterial vaccine adjuvants. Kdo₂-lipid A has not been chemically synthesized to date and could only be isolated from an Escherichia coli mutant strain, WBB06. WBB06 cells grow slowly and have to grow in the presence of tetracycline. In this study, a novel E. coli mutant strain, WJW00, that could synthesize Kdo2-lipid A was constructed by deleting the rfaD gene from the genome of E. coli W3110. The rfaD gene encodes ADP-L-glycero-D-manno-heptose-6-epimerase RfaD. Based on the analysis by SDS-PAGE, thin layer chromatography (TLC) and electrospray ionization mass spectrometry (ESI/MS), WJW00 could produce similar levels of Kdo₂-lipid A to WBB06. WJW00 cells grow much better than WBB06 cells and do not need to add any antibiotics during growth. Compared with the wild-type strain, W3110, WJW00 showed increased hydrophobicity, higher cell permeability, greater autoaggregation and decreased biofilm-forming ability. Therefore, WJW00 could be a more suitable strain than WBB06 for producing Kdo₂-lipid A and a good base strain for developing lipid A adjuvants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.